Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis

[1]  Yun Xu,et al.  IL-37 Represses the Autoimmunity in Myasthenia Gravis via Directly Targeting Follicular Th and B Cells , 2020, The Journal of Immunology.

[2]  V. Njike,et al.  Differential response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study , 2020, Journal of the Neurological Sciences.

[3]  S. Luo,et al.  HLA in myasthenia gravis: From superficial correlation to underlying mechanism. , 2019, Autoimmunity reviews.

[4]  C. Quan,et al.  Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis , 2019, Journal of Neuroimmunology.

[5]  Leana Doherty,et al.  Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis , 2019, Neuromuscular Disorders.

[6]  V. Goyal,et al.  Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study , 2019, Journal of Neurology.

[7]  F. Zimprich,et al.  High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria , 2019, Journal of Neurology.

[8]  M. Dalakas.  Immunotherapy in myasthenia gravis in the era of biologics , 2018, Nature Reviews Neurology.

[9]  Z. Siddiqi,et al.  Rituximab in refractory myasthenia gravis: Extended prospective study results , 2018, Muscle & nerve.

[10]  A. Punga,et al.  Advances in autoimmune myasthenia gravis management , 2018, Expert review of neurotherapeutics.

[11]  M. Guiguet,et al.  Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. , 2018, Journal of neuromuscular diseases.

[12]  C. Quan,et al.  Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis , 2017, Journal of Neuroimmunology.

[13]  S. Teerenstra,et al.  Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial , 2017, Trials.

[14]  F. Shi,et al.  Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder , 2017, JAMA neurology.

[15]  R. Tandan,et al.  Rituximab treatment of myasthenia gravis: A systematic review , 2017, Muscle & nerve.

[16]  F. Bolgert,et al.  Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients , 2017, Neuromuscular Disorders.

[17]  G. Wolfe,et al.  Rituximab in Treatment-Refractory Myasthenia Gravis. , 2017, JAMA neurology.

[18]  J. Goldstein,et al.  Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody–Positive Myasthenia Gravis , 2017, JAMA neurology.

[19]  F. Shi,et al.  Augmentation of Circulating Follicular Helper T Cells and Their Impact on Autoreactive B Cells in Myasthenia Gravis , 2016, The Journal of Immunology.

[20]  Andreas Radbruch,et al.  Plasma cells as an innovative target in autoimmune disease with renal manifestations , 2016, Nature Reviews Nephrology.

[21]  Nils E Gilhus.  Myasthenia Gravis. , 2016, The New England journal of medicine.

[22]  Y. Qi,et al.  Remarkably increased resistin levels in anti-AChR antibody-positive myasthenia gravis , 2015, Journal of Neuroimmunology.

[23]  V. Damato,et al.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis , 2015, Journal of Neurology.

[24]  Li Yang,et al.  Interleukin‐10 producing‐B cells and their association with responsiveness to rituximab in myasthenia gravis , 2014, Muscle & nerve.

[25]  D. Sanders,et al.  Prolonged B‐Cell Depletion in MuSK Myasthenia Gravis Following Rituximab Treatment , 2013, Muscle & nerve.

[26]  Chunshui Yu,et al.  Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica , 2013, Neurology.

[27]  P. Vermersch,et al.  Rituximab in refractory and non‐refractory myasthenia: A retrospective multicenter study , 2012, Muscle & nerve.

[28]  E. Frohman,et al.  Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success , 2012, Multiple sclerosis.

[29]  J. Verschuuren,et al.  Long-lasting treatment effect of rituximab in MuSK myasthenia , 2012, Neurology.

[30]  J. Goldstein,et al.  Response of patients with refractory myasthenia gravis to rituximab: a retrospective study , 2011, Therapeutic advances in neurological disorders.

[31]  M. Farrugia,et al.  The use of rituximab in myasthenia gravis and Lambert–Eaton myasthenic syndrome , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[32]  A. Alshekhlee,et al.  Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals , 2009, Neurology.

[33]  R. Blesa,et al.  Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients , 2008, Journal of Neuroimmunology.

[34]  S. Amadori,et al.  Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults , 2007, Haematologica.

[35]  I. Sanz,et al.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.